Chroma Therapeutics, Invitrogen deal

The companies extended a 2006 deal to use Invitrogen’s SelectScreen platform to screen Chroma’s multi-targeted kinase inhibitors. The deal is renewable quarterly. Chroma, which focuses on cancer and i...